Holen Sie sich die Stockscreener-App
1.88
0.00%
0.00
Skye Bioscience Inc Aktie (SKYE) Neueste Nachrichten
Skye Bioscience Inc (SKYE) Stock Price, Quote, News & History - Benzinga
SKYE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Skye Bioscience (SKYE) Shares Rise 6% After Hours: Here's What's Driving The Move - Benzinga
Total debt per share of Skye Bioscience, Inc. – FWB:09R0 - TradingView
Price to book forward of Skye Bioscience, Inc. – FWB:09R0 - TradingView
Operating margin % of Skye Bioscience, Inc. – FWB:09R0 - TradingView
Skye Bioscience, Inc. Income Statement – FWB:09R0 - TradingView
Skye BioscienceEnters $22 Million Securities Purchase Agreement With Redmile Biopharma Investments IiiSEC Filing - TradingView
Skye Bioscience Secures Up to $22 Million ELOC and Issues $5 Million Warrant to Redmile - TradingView
Skye Bioscience director Andrew Schwab sells $140,313 in stock By Investing.com - Investing.com India
Skye Bioscience director Andrew Schwab sells $140,313 in stock - Investing.com
5am Partners VII, LLC sells $140,313 of Skye Bioscience stock - Investing.com
Skye Bioscience (SKYE) insider funds sell 375,840 shares at $0.32–$0.41 - Stock Titan
Skye Bioscience (SKYE) 5AM funds sell at penny-level prices - Stock Titan
5AM Partners VII disposes of 375,840 Skye Bioscience shares worth $134,482.80 - Bitget
Skye Bioscience, Inc. Common Stock (NASDAQ: SKYE) Share Price, SKYE Stock News, SKYE Share Price & Updates - Kalkine
Form 8K Skye Bioscience Inc For: 19 August By Investing.com - Investing.com South Africa
Skye Bioscience flags Nasdaq noncompliance after stockholders’ equity falls to ($497,307) - Bitget
SKYE BIOSCIENCE INC(SKYE) Stock Options Chain | Quotes & News - Moomoo
Skye Bioscience Faces Nasdaq Compliance and Delisting Risk - TipRanks
Skye Bioscience receives Nasdaq notice for non-compliance with equity listing rule - Investing.com
Skye Bioscience Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Skye Bioscience (NASDAQ: SKYE) faces deadline to fix negative equity - Stock Titan
Skye Bioscience (SKYE) holder sells shares, funds Redx merger - Stock Titan
Skye Bioscience Inc (SKYE) (Q2 2026) Earnings Call Highlights: S - GuruFocus
$125m financing to see Macclesfield’s Redx list on Nasdaq - businesscloud.co.uk
Skye Bioscience, Inc. (SKYE) Skye Bioscience, Inc.M&A CallSlideshow (NASDAQ:SKYE) 2026-08-16 - Seeking Alpha
Skye (SKYE) Drops -7.21% — Key Support at $0.47 2026-08-15Sign of Weakness - vinanet.vn
Skye drops obesity program, combines with Redx to form Fibrx - AllSci
Redx tries again at reverse merger, with Skye this time, as alternative route gains steam - Endpoints News
Skye Bioscience Q2 Loss Narrows Sharply on Lower R&D Spending - Minichart
SKYE: Merger creates Fibrx, a well-funded fibrosis company advancing RXC008 for Crohn's disease - TradingView
Skye Bioscience to Be Acquired by Redx Pharma in $264.5M Nasdaq-Listed Merger - Minichart
SKYE: Merger creates a well-funded fibrosis company advancing RXC008 for Crohn's disease, with phase II data due 2029 - TradingView
Form 8K Skye Bioscience Inc For: 14 August By Investing.com - Investing.com Nigeria
Skye Bioscience to acquire Redx Pharma in $125M deal By Investing.com - Investing.com Nigeria
Skye Bioscience to acquire Redx Pharma in $125M deal - Investing.com
Skye Bioscience to Acquire Redx; Secures $67.9M Financing and $22M Equity Line - TradingView
Skye Bioscience, Inc. 2026: Revenue $178.2K, EPS ($0.27) — 10-Q Summary - TradingView
Skye Bioscience (NASDAQ: SKYE) exits obesity trial, pursues Redx merger and $100M+ funding - Stock Titan
Skye Bioscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings - marketscreener.com
SKYE BIOSCIENCE: QTRLY EPS $-0.27SEC FILING - webull.com
Skye Bioscience, Inc. announced that it expects to receive $89.9 million in funding from Redmile Group, LLC, Nextbio Capital Management LP, 5AM Venture Management, LLC, Abingworth LLP, British Patient Capital Limited and other investors. - marketscreener.com
Skye Bioscience (SKYE) Climbs 1.66% to $0.55: Consolidation Nears a Critical JunctureRating Change - Vinanet
Skye Bioscience (SKYE) Moves Higher: Can Bulls Clear $0.58 Resistance?Jelly Roll Trade - dars.gov.et
SKYE SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Skye Bioscience (SKYE) Jumps 10% as Shares Approach Key $0.55 ResistanceLong Setup Ideas - dars.gov.et
Skye Bioscience Inc (SKYE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Skye Bioscience Inc (SKYE) Stock News Today - TradingKey
SKYE Stockholders Have Opportunity to Lead Skye Bioscience, Inc - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages Skye Bioscience, In - The National Law Review
SKYE Q2'26 Earnings: EPS estimate is (0.24) USD - TradingView
Bronstein, Gewirtz & Grossman, LLC Is Investigating Skye Bioscien - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Skye Bioscience, Inc. (SKYE) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Skye Bioscience Inc expected to post a loss of 25 cents a shareEarnings Preview - TradingView
Skye Bioscience, Inc. Revenue Breakdown – NASDAQ:SKYE - TradingView
Skye Bioscience Inc. (SKYE) Q1 2026 Earnings: Clinical-Stage Losses Slightly Wider Than ConsensusEPS Surprise History - dars.gov.et
0.61%
3.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):